1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Estonia Pharmaceuticals and Healthcare Report Q4 2016

Estonia Pharmaceuticals and Healthcare Report Q4 2016

  • October 2016
  • -
  • Business Monitor International
  • -
  • 85 pages

Includes 3 FREE quarterly updates

BMI View:

Estonia's healthcare system is much more mature than its Central and Eastern European peers, but given the country's limited resources, its appeal to pharmaceutical companies will wane. Drugmakers can expect to see constrained revenue growth in the country as pricing pressures and restrictive drug reimbursement will be employed by the Estonian health insurance fund to restrict healthcare expenditure.


Headline Expenditure Projections

- Pharmaceuticals: Pharmaceutical spending will rise from EUR310mn (USD340mn) in 2015 to EUR330mn (USD360mn) in 2016, up 6.1% in local currency terms and up 7.2% in US dollar terms. Forecast in US dollar terms increased from last quarter.

- Healthcare: Spending will rise from EUR1.30bn (USD1.41bn) in 2015 to EUR1.39bn (USD1.53bn) in 2016, up 7.2% in local currency terms and up 8.3% in US dollar terms. Forecast has been increased slightly from last quarter. Estonia scores 55.7 out of 100 in BMI's Pharmaceutical Risk/Reward Index for Central and Eastern Europe in Q416, ranking in eighth place, same as in the previous quarter. Estonia's Industry rewards score is still the weakest link in its pharmaceutical profile, at 16.4, below the regional average of 20.0. Estonia's score for this indicator is above the regional average and one of the best scores in the table. Estonia has above average scores in the urban/rural split and pensionable population.

Table Of Contents

Estonia Pharmaceuticals and Healthcare Report Q4 2016
BMI Industry View 7
Table: Headline Pharmaceuticals and Healthcare Forecasts (Estonia 2014-2020) 7
SWOT 9
Industry Forecast 11
Pharmaceutical Market Forecast 11
Table: Pharmaceutical Sales, Historical Data And Forecasts (Estonia 2012-2020) 13
Healthcare Market Forecast 14
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Estonia 2012-2020) 17
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Estonia 2012-2020) 17
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Estonia 2012-2020) 17
Prescription Drug Market Forecast 18
Table: Leading Anatomical Therapeutic Chemical (ATC) Groups By Pharmaceutical Sales, 2004-2010 (%) 19
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Estonia 2012-2020) 21
Patented Drug Market Forecast 22
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Estonia 2012-2020) 23
Generic Drug Market Forecast 24
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Estonia 2012-2020) 25
OTC Market Forecast 26
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Estonia 2012-2020) 27
Pharmaceutical Trade Forecast 28
Table: Pharmaceutical Trade Data And Forecasts (Estonia 2014-2020) 29
Table: Pharmaceutical Trade Data And Forecasts local currency (Estonia 2014-2020) 29
Pharmaceuticals Risk/Reward Index 30
Central And Eastern Europe Risk/Reward Index - Q4 2016 30
Estonia Risk/Reward Index 37
Rewards 37
Risks 37
Regulatory Review 39
Intellectual Property Issues 42
Pricing Regime 43
Reimbursement Regime 44
Table: Key Health Insurance Indicators, 2007-2011 44
Table: Expenditure By Reimbursed Prescription Medicinal Products, 2005-2010 (EEK '000) 46
Market Overview 47
Healthcare Sector 48
Table: Healthcare Resources (Estonia 2010-2015) 50
Table: Healthcare Personnel (Estonia 2010-2015) 51
Table: Healthcare Activity (Estonia 2010-2015) 51
Table: HIF Healthcare Expenditure, 2006-2011 (EURmn) 52
Estonia Pharmaceuticals and Healthcare Report Q4 2016$$
Table: Reimbursement Spending By Key Therapeutic Area, 2010-2011 (EURmn) 54
Table: Medicinal Products Reimbursed For Insured Patients, 2009-2011 (EURmn) 55
Research And Development 56
Table: Members Of EBio, 2011 56
Clinical Trials 58
Table: Leading Causes Of Death, 2005-2010 61
Competitive Landscape 63
Research-Based Industry 63
Table: Members Of The Association Of International Pharmaceutical Manufacturers In Estonia 64
Table: Table: Multinational Market Activity 64
Generic Drugmakers 65
Pharmaceutical Distribution 66
Pharmaceutical Retail Sector 67
Table: Pharmacies And Pharmacy Market Ratios, 2004-2009 68
Company Profile 70
Grindeks 70
Demographic Forecast 74
Table: Population Headline Indicators (Estonia 1990-2025) 75
Table: Key Population Ratios (Estonia 1990-2025) 75
Table: Urban/Rural Population and Life Expectancy (Estonia 1990-2025) 76
Table: Population By Age Group (Estonia 1990-2025) 76
Table: Population By Age Group % (Estonia 1990-2025) 77
Glossary 79
Methodology 81
Pharmaceutical Expenditure Forecast Model 81
Healthcare Expenditure Forecast Model 81
Notes On Methodology 82
Risk/Reward Index Methodology 83
Index Overview 84
Table: Pharmaceutical Risk/Reward Index Indicators 84
Indicator Weightings 85

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.